Cardiotoxicity of copper-based antineoplastic drugs casiopeinas is related to inhibition of energy metabolism

Toxicology and Applied Pharmacology

Volumn 212, Issue 1, 2006, Pages 79-88

  Hernández Esquivel, Luz ^a   Marín Hernández, Alvaro ^a   Pavón, Natalia ^a   Carvajal, Karla ^a   Moreno Sánchez, Rafael ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

2 oxoglutarate dehydrogenase; Cardiotoxicity; Creatine kinase; Oxygen consumption; Pyruvate dehydrogenase; Work performance

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALBUMIN; ANTINEOPLASTIC AGENT; CASIOPEINA II GLY; CASIOPEINA III I A; CISPLATIN; COPPER; CREATINE KINASE; CREATINE PHOSPHATE; DOXORUBICIN; GLUCOSE; OCTANOIC ACID; OXOGLUTARATE DEHYDROGENASE; PYRUVATE DEHYDROGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DRUG BINDING; DRUG INHIBITION; DRUG TARGETING; DRUG TISSUE LEVEL; ENERGY METABOLISM; HEART; HEART FUNCTION; HEART RATE; HEART WORK; IC 50; IN VIVO STUDY; MUSCLE FIBRIL; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PERFUSION AND SUPERFUSION; RAT; THORAX SURGERY;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CISPLATIN; COPPER; DATA INTERPRETATION, STATISTICAL; DOXORUBICIN; ENERGY METABOLISM; HEART DISEASES; HEART FUNCTION TESTS; HEART RATE; MALE; MYOCARDIAL CONTRACTION; MYOCARDIUM; ORGANOMETALLIC COMPOUNDS; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; RATS;

ANIMALIA;

EID: 33644961413     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2005.06.023     Document Type: Article

References (34)

1. A. Ace The cardiotoxicity of chemotherapeutic drugs Semin. Oncol. 19 1992 529 542
2. K. Anflous, V. Veksler, P. Mateo, F. Samson, V. Saks, and R. Ventura-Clapier Mitochondrial creatine kinase isoform expression does not correlate with its mode of action Biochem. J. 322 1997 73 78
3. G. Ara, T. Kusumoto, T.T. Korbut, F. Cullere-Luengo, and B.A. Teicher Cisdiamminedichloro platinum (II) resistant human tumor cell lines are collaterally sensitive to PtCl4 (RH-123)2: evidence for mitochondrial involvement Cancer 54 1994 1497 1502
4. H.U. Bergmeyer Methods of Enzymatic Analysis vol. III 1983 Verlag-Chemie Weinheim
5. K. Carvajal, and R. Moreno-Sánchez Heart metabolic disturbances in cardiovascular diseases Arch. Med. Res. 34 2003 89 99
6. K. Carvajal, M. El Hafidi, and G. Baños Myocardial damage due to ischemia and reperfusion in hypertriglyceridemic and hypertensive rats: participation of free radicals and calcium overload J. Hypertens. 17 1999 1607 1616
7. K. Carvajal, G. Baños, and R. Moreno-Sánchez Impairment of glucose metabolism and energy transfer in the hypertriglyceridemic rat heart Mol. Cell. Biochem. 249 2003 157 165
8. S.M. De Atley, S. Aksenov, M.Y. Aksenova, M.V. Jordan, J.M. Carney, and A.D. Butterfield Adriamycin-induced changes of creatine kinase activity in vivo and in cardiomyocyte culture Toxicology 134 1999 51 62
9. S.S. De Graaf, A. Nijmeijer, and W.G. Zijlstra Acute circulatory effects of doxorubicin in the conscious dog Pediatr. Hematol. Oncol. 3 1986 311 318
10. A. De-Vizcaya-Ruiz, A. Rivero-Mueller, L. Ruiz-Ramirez, G.E. Lass, L.R. Kelland, R.M. Orr, and M. Dobrota Induction of apoptosis by a novel copper-based anticancer compound, casiopeina II, in L1210 murine leukaemic and CHI human ovarian carcinoma cells Toxicol. In Vitro 14 2000 1 5
11. A. De Vizcaya-Ruiz, A. Rivero.Müller, L. Ruiz-Ramírez, J.A. Howarth, and M. Dobrota Hematotoxicity response in rats by the novel copper-based anticancer agent: casiopeina II Toxicology 194 2003 103 113
12. J.F. Ensley, J.R. Jacobs, A. Weaver, J. Kinzie, J. Crissman, J.A. Kish, G. Cummings, and M. Al-Sarraf Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck Cancer 54 1984 811 814
13. I. Fuentes-Noriega, L. Ruiz-Ramírez, A. Tovar Tovar, H. Rico-Morales, and I. Gracia-Mora Development and validation of a liquid chromatographic method for casiopeina IIIi in rat plasma J. Chromatogr., B 772 2002 115 121
14. R.S. Goldstein, and G.S.H. Mayor The nephrotoxicity of cisplatin Life Sci. 32 1983 685 690
15. I. Gracia-Mora, L. Ruiz-Ramirez, C. Gómez-Ruiz, M. Tinoco-Méndez, A. Márquez-Quiñones, L. Romero-De Lira, A. Marín-Hernández, L. Macías-Rosales, and M.E. Bravo-Gómez Knight's move in the periodic table, from copper to platinum, novel antitumor mixed chelate copper compounds, casiopeinas, evaluated by an in vitro human and murine cancer cell line panel Met.-Based Drug. 8 2001 19 28
16. 2+ in pyruvate dehydrogenase interconversion in brain mitochondria and synaptosomes Biochem. J. 227 1985 129 136
17. R.G. Hansford, and L. Cohen Relative importance of pyruvate dehydrogenase interconversion and feed-back inhibition in the effect of fatty acids on pyruvate oxidation by rat heart mitochondria Arch. Biochem. Biophys. 191 1978 65 81
18. F.M.H. Jeffrey, V. Diczku, A.D. Sherry, and C.R. Malloy Substrate selection in the isolated working rat heart: effects of reperfusion, afterload, and concentration Basic Res. Cardiol. 90 1995 388 396
19. O.H. Lowry, N.J. Rosenbrough, A.L. Ferr, and R.J. Randall Protein measurement with the folin phenol reagent J. Biol. Chem. 14 1951 425 449
20. A. Marin-Hernández, I. Gracia-Mora, L. Ruiz-Ramirez, and R. Moreno-Sanchez Toxic effects of copper-based antineoplastic drugs (casiopeinas) on mitochondrial functions Biochem. Pharmacol. 65 2003 1979 1989
21. U. Minhaz, S. Koide, A. Shohtsu, M. Fujishima, and H. Nakazawa Perfusion delays causes unintentional ischemic preconditioning in isolated heart preparation Basic Res. Cardiol. 90 1995 418 423
22. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol. Rev. 56 2004 185 229
23. R. Moreno-Sánchez, S. Devars, F. López-Gómez, A. Uribe, and N. Corona Distribution of control of oxidative phosphorylation in mitochondria oxidizing NAD-linked substrates Biochim. Biophys. Acta 1060 1991 284 292
24. P.C. Pelikan, G. Gerstenblith, K. Vandegaer, and W.E. Jacobus Absence of acute doxorubicin-induced dysfunction of heart mitochondrial oxidative phosphorylation and creatine kinase activities Proc. Soc. Exp. Biol. Med. 188 1988 7 16
25. S.W. Rabkin, and M. Ohmae Effects of doxorubicin (adriamycin) on systemic hemodynamics and myocardial blood flow Pharmacology 25 1982 272 277
26. S. Rajagopalan, P.M. Politi, B.K. Sinha, and C.E. Myers Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity Cancer Res. 48 1988 4766 4769
27. L. Reyes, I. Fuentes-Noriega, L. Ruiz-Ramírez, and L. Macías Development and validation of a liquid chromatographic method for casiopeina IIgly in rat plasma J. Chromatogr., B 791 2003 111 116
28. J.S. Rodríguez-Zavala, J.P. Pardo, and R. Moreno-Sánchez Modulation of 2-oxoglutarate dehydrogenase complex by inorganic phosphate, Mg2+, and other effectors Arch. Biochem. Biophys. 379 2000 78 84
29. Ruiz Azuara, L., U.S. Patent A. 21, 1992. Number 5, 1027, 005. US Patent Re 35, 458 February 18, 1997. US Patent November 19, 1996. Number 5,576,326. 407543 SECOFI; 1993.
30. M. Tokarska-Schlattner, T. Wallimann, and U. Schlattner Multiple interference of anthracyclines with mitchondrial creatine kinases: preferential damage of the cardiac isoenzyme and its implications for drug cardiotoxicity Mol. Pharmacol. 61 2002 516 523
31. K.B. Wallace Doxorubicin-induced cardiac mitochondrionopathy Pharmacol. Toxicol. 93 2003 105 115
32. 2 and p53 independent pathways J. Biol. Chem. 270 2004 25535 25543
33. S.D. Williams, and L.H. Einhorn Cisplatinum in the treatment of testicular and other cancers Adv. Intern. Med. 27 1982 531 545
34. S. Zhou, A. Starkov, M.K. Froberg, R.L. Leino, and K.B. Wallace Cumulative and irreversible cardiac mitochondrial dysfunction Cancer Res. 61 2001 771 777